Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Non-Current Liabilities (2021 - 2025)

Historic Total Non-Current Liabilities for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q3 2025 value amounting to $22.1 million.

  • Barinthus Biotherapeutics' Total Non-Current Liabilities fell 1986.39% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year decrease of 1986.39%. This contributed to the annual value of $27.5 million for FY2024, which is 721.74% up from last year.
  • Per Barinthus Biotherapeutics' latest filing, its Total Non-Current Liabilities stood at $22.1 million for Q3 2025, which was down 1986.39% from $24.5 million recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Total Non-Current Liabilities peaked at $32.6 million during Q3 2023, and registered a low of $22.1 million during Q3 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' median Total Non-Current Liabilities value was $26.5 million (recorded in 2023), while the average stood at $26.8 million.
  • In the last 5 years, Barinthus Biotherapeutics' Total Non-Current Liabilities surged by 1430.88% in 2023 and then plummeted by 1986.39% in 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Total Non-Current Liabilities (Quarter) stood at $25.8 million in 2021, then fell by 1.9% to $25.3 million in 2022, then increased by 1.56% to $25.7 million in 2023, then rose by 7.22% to $27.5 million in 2024, then decreased by 19.64% to $22.1 million in 2025.
  • Its last three reported values are $22.1 million in Q3 2025, $24.5 million for Q2 2025, and $23.8 million during Q1 2025.